ATNM

Actinium Pharmac

• TipRanks·05/12 10:27

  Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts

• TipRanks·04/22 16:15

  Reinforced Buy on Actinium: Strengthening ATNM-400 Pan-Tumor Data and Expanding Actimab-A AML Opportunities Drive Pipeline Upside

• TipRanks·04/22 11:29

  Actinium presents data from Actimab-A studies at AACR

• TipRanks·04/22 11:23

  Actinium presents preclinical results for ATNM-400 at AACR

• Benzinga·04/22 11:08

  Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mechanism Driving Mutation-Agnostic Anti-Leukemic Activity Of Actimab-A In AML

• Benzinga·04/22 11:06

  Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer Models Presented At AACR Annual Meeting

• PR Newswire·04/22 11:00

  Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

• TipRanks·04/08 19:05

  Actinium Pharmaceuticals: Undervalued Radiopharmaceutical Play with Promising ATNM-400 Pipeline and Near‑Term Catalysts

• PR Newswire·04/06 11:30

  Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

• TipRanks·04/03 07:10

  Analysts Are Bullish on Top Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Actinium Pharmaceuticals (ATNM)

• Dow Jones·03/31 13:18

  Actinium Pharmaceuticals Price Target Maintained With a $5.00/Share by Stephens & Co.

• Benzinga·03/31 13:08

  Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

• TipRanks·03/31 10:39

  Actinium Pharmaceuticals (ATNM) Gets a Buy from H.C. Wainwright

• Benzinga·02/17 12:46

  Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026

• PR Newswire·02/17 12:42

  Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting